Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.64 USD | 0.00% | +0.61% | -44.03% |
04-11 | BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target | MT |
04-02 | HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating | MT |
Sales 2024 * | 16.93M 1.36B | Sales 2025 * | 13.83M 1.11B | Capitalization | 68.13M 5.45B |
---|---|---|---|---|---|
Net income 2024 * | -58M -4.64B | Net income 2025 * | -69M -5.52B | EV / Sales 2024 * | 4.02 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.93 x |
P/E ratio 2024 * |
-1.27
x | P/E ratio 2025 * |
-1.23
x | Employees | 107 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.27% |
1 week | +0.61% | ||
Current month | -27.75% | ||
1 month | -26.79% | ||
3 months | -23.72% | ||
6 months | -40.36% | ||
Current year | -44.03% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 34 | 31/12/15 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 31/01/18 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 31/05/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 31/01/18 |
Sanford Zweifach
CHM | Chairman | 68 | 31/10/21 |
Director/Board Member | 66 | 31/01/22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.64 | 0.00% | 54,732 |
25/04/24 | 1.64 | -2.38% | 112,570 |
24/04/24 | 1.68 | -1.18% | 50,919 |
23/04/24 | 1.7 | -9.09% | 135,661 |
22/04/24 | 1.87 | +14.72% | 144,126 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.03% | 68.13M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CARM Stock